Table 3. Malignant lymphomas, unclassified leukemias and thymus hyperplasia.
| Vector | Primary Animal | Secondary Animal | Premature Death (Days) or TS | HLP Change | Staining CD3+CD45RA- | Staining CD45.2/CD45.1 |
|---|---|---|---|---|---|---|
| Malignant cells | ||||||
| HPV569 | M21 | M104 | 140 | LEUK | - | equivocal |
| F42 | 203 | ML(S) | + | equivocal | ||
| M25 | M108 | 186 | ML(S) | + | equivocal | |
| F10 | F9 | TS | ML(T2) | + | equivocal | |
| F13 | F12 | TS | ML(T1) | + | CD45.2 | |
| F16 | M76 | TS | ML(T1) | + | CD45.2 | |
| F15 | 142 | LEUK | - | equivocal | ||
| BB305 | M14 | M101 | TS | ML(S) | + | equivocal |
| M24 | M107 | TS | ML(S) | + | CD45.1 | |
| M27 | F48 | TS | ML(S) | + | CD45.1 | |
| F14 | F13 | 192 | ML(S) | + | equivocal | |
| F17 | M77 | TS | ML(S) | + | CD45.2 | |
| F22 | F22 | TS | ML(T2) | + | equivocal | |
| Mock | M18 | F58 | TS | ML(S) | + | equivocal |
| F12 | F11 | TS | ML(S) | + | CD45.2 | |
| Hyperplasia | ||||||
| HPV569 | M7 | F34 | TS | TLH | + | nd |
| BB305 | M22 | M105 | TS | TLH | + | nd |
| F26 | M86 | TS | TLH | + | nd | |
| F28 | F26 | TS | TLH | + | nd | |
TS: Terminal sacrifice (6.8 months post-transplantation); HLP: Hemato-lymphopoietic change; +: CD3+CD45RA-cells; -: CD3-CD45RA-cells; equivocal: either no or faint staining of a low proportion of lymphomatous cells, LEUK: Leukemia, not otherwise specified; ML: Malignant lymphoma (S: systemic; T1: thymic, 1 lobe; T2: thymic, 2 lobes); TLH: Thymic lymphoid hyperplasia; nd: not done.